Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab and Bevacizumab in Recurrent, Persistent or Metastatic Cervical Cancer
NCT02921269Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Mar 2017
- Primary completion
- Oct 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab in Cervical Cancer (CC), sponsored by National Cancer Institute. Primary endpoint: Objective Response Rate at 2 years. Started Mar 2017; status: completed.
02
Drugs
atezolizumab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT02921269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02921269.